Evaluation the effects of Oxycodone administration on pain control in patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150107020592N24

Enrollment

Registered

2020-06-08

Start date

2020-03-20

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19 Disease

Interventions

Intervention group: Patients hospitalized in the intensive care unit with covid disease who complain of pain will be treated with two oxycodone 5 mg tablets every eight hours during their hospitalizat

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Covid-19 patients Patients hospitalized in the intensive care unit

Exclusion criteria

Exclusion criteria: Patients with dissatisfaction with drug use

Design outcomes

Primary

Measure	Time frame
Pain in hospitalized patients based on the pain questionnaire. Timepoint: The first to seventh days after the onset of oxycodone. Method of measurement: Pain scale (VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

smrhashemian@sbmu.ac.ir+98 912 111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026